Nonetheless, the discriminative power of RIBER is significant and we believe it will be a useful tool, in particular in situations, where the selection of most promising crystals for the diffraction and structure solution is a crucial factor to maximize the success in structure determination.
"His operational experience in Internet advertising and his proven success in structuring and scaling global organizations make him the perfect fit for Yahoo as we propel the business to its next phase of growth".
The main key to success in structure-based drug discovery is the accurate prediction of binding affinities of hit compounds.
As large firms accumulate power, however, they become systemically constrained by the embodiment of their recipe for success in structures such as physical facilities, production systems, union agreements, organizational hierarchies, promotion policies, government regulation and every other element of a corporate bureaucracy.
Such prediction of binding sites which depends on structural similarity of protein surfaces is useful and accurate and can enjoy success in structures with dissimilar folding patterns.
However, very few recent studies have used methods such as paternity or mating system analyses to estimate the importance of assortment and/or heterogeneity in mating success in structuring hybrid zones of plants (e.g. [ 19- 21]) or animals (e.g. [ 22]).
Recent successes in the structure determination of G-protein-coupled receptors (GPCRs) resulted from the development of GPCR-specific protein engineering strategies.
Statistical mechanics-based modeling has led to significant success in RNA structure prediction, folding stabilities, and folding kinetics for structures with different structural complexities (Liu et al. 2006; Chen 2008).
Knowledge-based approaches, which predict structural models using the regularities and rules of known protein structures seen in the Protein Data Bank (PDB) library, have enjoyed more extensive success in protein structure prediction [ 2- 4].
Instead of detailing success stories in structure-based drug discovery, the following article considers how future efforts to discover or design new drugs may increasingly rely on information about molecular targets and less on data acquired via approaches involving random methodologies.
